Key result
Indomethacin blunted the increase in calf blood flow during ketosis compared to placebo and prevented cardiac alterations in IDDM patients.
Why the study?
Does indomethacin reduce hemodynamic abnormalities during short-term insulin deficiency in IDDM patients?
RCT (n=19)
Double-blind
Randomized
Does indomethacin reduce hemodynamic abnormalities during short-term insulin deficiency in IDDM patients?
Prostaglandin inhibition with indomethacin significantly blunts the vascular and cardiac hemodynamic alterations induced by acute insulin deficiency in patients with type 1 diabetes.
Answers are grounded in this paper and cite their sources.
Indomethacin may mitigate hemodynamic instability in acute insulin deficiency; extends RCT evidence for prostaglandin inhibition in type 1 diabetes.
It has been suggested that the hemodynamic derangements present in diabetic ketoacidosis are the results not only of profound volume depletion but also of the effects of increased production of vasodilating prostaglandins (PGs), principally PGI2, released by adipose tissue. In animal and in vitro models, prostaglandin synthesis is increased during insulin deficiency. We assessed the effects of short-term ketosis on the metabolic and hemodynamic variables of 10 IDDM patients free from long-term complications and of 9 normal control subjects after a 7-day randomized double-blind indomethacin (INDO) (50 mg q.i.d.) or placebo treatment period. Calf blood flow (CBF), postocclusive reactive hyperemia (PORH), and recovery half-time (an index of overall perfusion) after PORH were measured by plethysmography. Left ventricular and myocardial functions were also studied in each different condition during placebo and INDO treatment in IDDM patients. During placebo treatment, the increase in CBF during ketosis was higher (1.75 +/- 0.29 ml / min / 100 ml muscle) than during INDO (0.85 +/- 0.17 ml / min) / 100 ml muscle; P = 0.007). PORH was similar in baseline conditions, during ketosis, and in recovery in both the placebo and INDO arms. Recovery half-time significantly increased during placebo (10 +/- 2; 200%; P < 0.01) but not during INDO (1 +/- 1; 106%; NS) treatment. In normal control subjects, insulin deficiency did not induce any significant effect on hemodynamic variables. In IDDM patients, during placebo treatment, ketosis increased both the cardiac index (from 3.4 +/- 0.7 to 4.1 +/- 0.81 / min / m; P < 0.01) and the stroke index (from 42 +/- 8 to 49 +/- 7 ml/m2; P < 0.01) without changes in left ventricular ejection fraction but with a significant increase in both left and right ventricular end-diastolic volumes. Metabolic recovery induced a normalization of these parameters. INDO treatment significantly blunted these alterations. In summary, we showed that during acute insulin deficiency, INDO-sensitive mechanisms mediate vascular disturbances. Moreover, INDO treatment was capable of completely preventing the cardiac venous return and the left ventricular alterations. INDO does not interfere with the overall ketogenetic process or with insulin-induced metabolic recovery.
No takes yet. Share an insight, caveat, or question.
Avogaro et al. (1996) conducted an RCT in Insulin-Dependent Diabetes Mellitus (IDDM) (n=19). Indomethacin vs. Placebo was evaluated on Increase in calf blood flow during ketosis (p=0.007). Indomethacin blunted the increase in calf blood flow during ketosis compared to placebo and prevented cardiac alterations in IDDM patients.
Synapse has enriched 10 related papers. Consider them for comparative context: